康方生物:重要数据催化节点临近 “新管线”加速推进

华源证券
09 Apr

2024 年整体业绩符合预期。24 全年总收入为21.239 亿元,同比下降53.08%,主要是基于授权费用的减少,24 年从SUMMIT 收到的授权费用为1.216 亿元。24 年扣除分销成本后的商业销售收入为20.024 亿元,同比增长24.88%。24 年归母净利润-5.01 亿元。24 年全年研发开支11.88 亿元,同比-5.29%;销售及营销费用10.02亿元,同比+12.51%;行政...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10